Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
复制标题
吉西他滨、奥沙利铂和培门冬酶联合治疗（P-gemox 方案）对新诊断的晚期或复发/难治性结外 NK/T 细胞淋巴瘤患者的疗效。
DOI：
10.18632/oncotarget.8647
复制
发表时间：
2016-05-17
期刊：
影响因子：
--
通讯作者：
Lu Y
中科院分区：
文献类型：
--
作者：
Wang JH;Wang L;Liu CC;Xia ZJ;Huang HQ;Lin TY;Jiang WQ;Lu Y
结外自然杀伤/T细胞淋巴瘤(ENKTL)是一种侵袭性较强、预后较差的肿瘤。对于晚期或复发/难治的ENKTL患者，建议使用基于天冬酰胺酶的方案。我们回顾研究了吉西他滨、奥沙利铂和聚谷氨酸乙酯合用(P-Gemox)在这些患者中的疗效和毒性。对35例初诊为III~IV期、复发或难治性ENKTL患者采用P-吉西他滨(1250 mg/m2)和奥沙利铂(85 mg/m2)静脉注射2~8个周期，并于第1天肌肉注射派拉帕酶(2500 IU/m2)，每2周重复一次。治疗结束时，总有效率为80.0%，51.4%的患者完全缓解。1、2、3年无进展生存率分别为45.0%、38.6%、38.6%，总生存率分别为76.8%、64.7%、64.7%。完全缓解的患者比完全缓解的患者无进展生存率更高(p=0.01)。主要不良反应为血液学毒性和肝功能障碍。40.0%的患者出现3/4度白细胞减少和中性粒细胞减少。没有发生与治疗相关的死亡。这些结果表明，P-Gemox方案是治疗新诊断的晚期或复发/难治性ENKTL的一种安全有效的方案。我们预计未来的前瞻性试验将证实该疗效。
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Asparaginase-based regimens are recommended for patients with advanced-stage or relapsed/refractory ENKTL. We retrospectively investigated the efficacy and toxicity of combined gemcitabine, oxaliplatin, and pegaspargase (P-gemox) in these patients. A total of 35 patients with newly diagnosed stage III–IV, relapsed or refractory ENKTL were treated with 2 to 8 cycles of P-gemox: gemcitabine (1250 mg/m2) and oxaliplatin (85 mg/m2) injected intravenously and pegaspargase (2500 IU/m2) injected intramuscularly on day 1 and repeated every 2 weeks. Upon completion of treatment, the overall response rate was 80.0%, with a complete response in 51.4% of patients. The 1-, 2- and 3- year progression-free survival rates were 45.0%, 38.6% and 38.6%, and overall survival rates were 76.8%, 64.7% and 64.7%, respectively. Patients who attained a complete response showed better progression-free survival than those without a complete response (p = 0.01). The major adverse effects were hematologic toxicity and liver dysfunction. Grade 3/4 leucopenia and neutropenia occurred in 40.0% of patients. No treatment-related deaths occurred. These results indicate the P-gemox regimen is a safe and effective treatment for patients with newly diagnosed advanced-stage or relapsed/refractory ENKTL. We anticipate future prospective trials will confirm the efficacy.
登录
查看更多内容
鼻型NK/T细胞淋巴瘤：临床特征和治疗结果。
影响因子：
8.8
作者：
Lee, J;Kim, WS;Park, YH;Park, SH;Park, KW;Kang, JH;Lee, SS;Lee, SI;Lee, SH;Kim, K;Jung, CW;Ahn, YC;Ko, YH;Park, K
通讯作者：
Park, K
影响因子：
3.1
作者：
Lopez, Andres;Gutierrez, Antonio;Rodriguez, Jose
通讯作者：
Rodriguez, Jose
影响因子：
20.3
作者：
Drenou, B;Lamy, T;Fauchet, R
通讯作者：
Fauchet, R
影响因子：
5.8
作者：
Dinndorf, Patricia Anne;Gootenberg, Joseph;Pazdur, Richard
通讯作者：
Pazdur, Richard
影响因子：
3
作者：
Faivre, S;Raymond, E;Cvitkovic, E
通讯作者：
Cvitkovic, E